PwPepwise

Melanotan I / Afamelanotide

Skin & Tanning

a.k.a. Scenesse

MC1R agonist

Afamelanotide (also known as Melanotan I) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring hormone.

§Dosing at a glance

3 protocols · from the research
What it's forDoseHow oftenHowFor how long
Erythropoietic Protoporphyria (EPP — Approved Indication)16 mg—SubcutaneousInjected just under the skin, into the fat layer.2 yrs
Vitiligo (Investigational — Combination Therapy)16 mg—SubcutaneousInjected just under the skin, into the fat layer.4 mos
Polymorphic Light Eruption (PLE — Investigational)16 mg—SubcutaneousInjected just under the skin, into the fat layer.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

Afamelanotide (also known as Melanotan I) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring hormone that regulates skin pigmentation and photoprotection. By binding to receptors in skin cells, it stimulates the production of melanin — the pigment responsible for skin darkening — which in turn helps protect the skin from ultraviolet (UV) radiation damage.

The most well-established application of afamelanotide is in erythropoietic protoporphyria (EPP), a rare and painful genetic disorder in which sunlight exposure triggers severe burning reactions. In clinical trials, afamelanotide significantly increases pain-free sun exposure time and improves quality of life for EPP patients1,10. It is approved in both Europe and the United States for this indication under the brand name Scenesse. Afamelanotide also improves repigmentation outcomes in vitiligo when combined with narrowband ultraviolet B (NB-UVB) phototherapy, achieving greater and faster repigmentation compared to phototherapy alone2. Research is actively exploring its potential in additional photodermatological conditions including polymorphic light eruption5,12, UV-induced DNA damage prevention15, and skin cancer prevention in immunocompromised patients8, with multiple registered trials currently underway.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Afamelanotide ([Nle4-D-Phe7]-α-MSH) is a tridecapeptide analog of endogenous alpha-melanocyte-stimulating hormone (α-MSH) in which leucine at position 4 is replaced by norleucine and phenylalanine at position 7 is substituted with its D-stereoisomer. These modifications confer markedly greater receptor binding affinity, metabolic stability, and biological potency relative to the native peptide, enabling sustained pharmacological activity following slow-release subcutaneous implant delivery.

Afamelanotide acts as a potent agonist at the melanocortin-1 receptor (MC1R), a G-protein-coupled receptor expressed predominantly on epidermal melanocytes. MC1R activation stimulates intracellular adenylyl cyclase, elevating cyclic AMP (cAMP) levels, which in turn activates protein kinase A (PKA) and drives transcription of the microphthalmia-associated transcription factor (MITF). MITF upregulates key melanogenic enzymes including tyrosinase, tyrosinase-related protein 1 (TRP-1), and dopachrome tautomerase (DCT), collectively promoting the biosynthesis of eumelanin — the photoprotective, dark-brown/black form of melanin. Eumelanin acts as a broad-spectrum UV absorber, scavenging reactive oxygen species and dissipating UV photon energy as heat, thereby reducing UV-induced DNA damage including cyclobutane pyrimidine dimer (CPD) formation. The capacity of afamelanotide to enhance UV-induced DNA damage prevention and DNA repair mechanisms is an active area of mechanistic clinical investigation15.

The immunogenicity assessment of afamelanotide demonstrated that despite structural divergence from endogenous α-MSH, no de novo anti-drug antibodies were induced in 23 of 26 EPP patients over up to 6 years of treatment, and pre-existing immunoreactivity did not increase with drug exposure13. This is consistent with the small peptide's limited antigenicity and supports sustained pharmacological activity throughout long-term administration.

Afamelanotide is delivered via a bioresorbable subcutaneous implant approximately 2 cm × 0.15 cm in size, designed to provide controlled release of the peptide over a period of several days following implantation, with the polymer matrix slowly dissolving after drug release4. This formulation circumvents the short plasma half-life limitations inherent to peptide therapeutics while minimizing peak-related systemic adverse effects. Plasma pharmacokinetics in EPP patients across adolescent and adult populations are being further characterized in ongoing clinical studies16. MC1R agonism by afamelanotide also has activity in non-melanocytic cell types expressing this receptor, which may contribute to anti-inflammatory and cytoprotective effects beyond the melanogenic pathway — biological relationships that ongoing research continues to characterize1,10.

§04Evidence & efficacy

Evidence base
215Studies
113Human
11Animal

Afamelanotide's efficacy is most rigorously established in erythropoietic protoporphyria (EPP), where it significantly increases pain-free sun exposure time and improves disease-specific quality of life. In the pivotal dual-cohort RCT, US patients experienced a median 69.4 versus 40.8 pain-free hours in sunlight (P=0.04), and EU patients experienced a median 6.0 versus 0.8 hours (P=0.005), compared to placebo1. The EU cohort also showed a significantly reduced number of phototoxic reactions (77 vs. 146, P=0.04)1. These results formed the regulatory basis for FDA and EMA approval of Scenesse for EPP. Real-world postauthorization data confirm durable clinical benefit, with afamelanotide associated with an increase of 6.1 hours of outdoor time per week (P<.001) and a 14.01% improvement in disease-specific quality of life scores (P<.001) over a median follow-up of approximately 2 years10.

In vitiligo, afamelanotide combined with NB-UVB phototherapy produces significantly superior repigmentation compared to NB-UVB monotherapy, achieving 48.64% versus 33.26% repigmentation at day 168 (P<0.05)2. Repigmentation onset is significantly faster on the face (41 vs. 61 days, P=0.001) and upper extremities (46 vs. 69 days, P=0.003) in the combination group2. The benefit appears most pronounced in patients with Fitzpatrick skin phototypes IV–VI2. A Phase III open-label trial is currently underway to further characterize these outcomes7.

Afamelanotide's potential to reduce UV-induced DNA damage and enhance DNA repair capacity is being actively investigated in healthy volunteers15, and its role in preventing actinic keratoses and squamous cell carcinomas in immunocompromised organ transplant recipients is an area of active clinical development8.

Evidence Rating: Strong (for EPP); Moderate (for vitiligo combination therapy); Preliminary (for all other indications)

Rating Rationale: The Strong EPP rating is supported by two independently conducted, adequately powered RCTs both meeting their prespecified primary endpoints1, corroborated by a postauthorization real-world study10, and culminating in dual regulatory approval. The Moderate vitiligo rating reflects a single well-designed multicenter RCT meeting its primary endpoint2, with replication pending from the ongoing Phase III trial7; notably, the efficacy benefit was concentrated in the Fitzpatrick IV–VI subgroup, with no significant benefit observed in SPT III patients. All other indications (PLE, DNA damage prevention, skin cancer chemoprevention) are supported only by trial registration records without published outcome data5,8,12,15, warranting a Preliminary designation.

§05Safety

Afamelanotide has demonstrated a consistently favorable safety and tolerability profile across extensive clinical evaluation spanning EPP, vitiligo, and healthy volunteer populations.

The most commonly reported adverse events are mild and self-limiting, including nausea, fatigue, and headache10. Transient skin darkening and hyperpigmentation are expected pharmacodynamic effects of melanocortin receptor agonism. Implant site reactions have been noted but are generally minor and well tolerated1,2. In the pivotal EPP trials, serious adverse events were not considered related to the study drug, and no major safety signals were identified1. In the vitiligo combination therapy trial, the afamelanotide plus NB-UVB group experienced erythema (seen in both groups), as well as minor infections and nausea, with no severe or life-threatening adverse events reported2.

The real-world clinical practice cohort reported only minor self-limiting adverse events over a median follow-up of approximately 2 years, with a treatment continuation rate of 98%, reflecting strong long-term tolerability in an approved-indication population10.

Long-term immunogenicity evaluation across patients treated for up to 6 years found no de novo anti-drug antibody formation in 23 of 26 patients. Three patients showed pre-existing immunoreactivity to both afamelanotide and endogenous α-MSH, but antibody titers remained stable and did not increase with continued drug exposure, indicating a low immunogenic risk profile13.

Pharmacological characterization of afamelanotide's adolescent safety profile is an active area of clinical investigation, with a dedicated pharmacokinetic study currently underway in EPP patients across adolescent and adult age groups16.

§06History

Afamelanotide emerged from the melanocortin peptide research programs of the 1980s and 1990s, originating from efforts to synthesize stabilized analogs of α-MSH with enhanced receptor potency and metabolic durability. The introduction of norleucine and D-phenylalanine substitutions yielded a compound with substantially greater MC1R affinity and in vivo stability than the native hormone. Early investigations explored melanocortin analogs for tanning and photoprotection applications, forming the scientific foundation for afamelanotide's therapeutic development.

Clinuvel Pharmaceuticals (then Epitan) advanced afamelanotide through clinical development, beginning with early phase studies characterizing its pharmacokinetics and melanogenic potential in healthy volunteers19. The company pursued the bioresorbable subcutaneous implant formulation as a novel drug delivery strategy to achieve sustained peptide release4, overcoming the rapid clearance that limits conventional peptide administration routes.

Afamelanotide received European Medicines Agency (EMA) approval in 2014 as Scenesse for the prevention of phototoxicity in adult EPP patients — the first approved therapy for this rare and debilitating orphan disease. FDA approval followed in 2019 for the same indication, marking a landmark regulatory achievement for peptide therapeutics in rare disease. The pivotal evidence supporting these approvals was consolidated in a landmark 2015 dual-cohort RCT publication1.

The vitiligo indication has been actively developed in parallel, with a positive Phase III RCT published in 2015 demonstrating superiority of afamelanotide plus NB-UVB over phototherapy alone2, and an ongoing Phase III trial currently underway7. Multiple additional indications including polymorphic light eruption5,12, UV-induced DNA damage prevention15, and skin cancer chemoprevention in immunocompromised patients8 represent the active frontier of afamelanotide's expanding clinical research landscape.

§07References